David S. Snyder, MD, FACP, Srdan Verstovsek, MD, PhD, and Ruben Mesa, MD, FACP
In this segment, “Next Steps in MPNs” David Snyder, MD, Srdan Verstovsek, MD, PhD and Ruben Mesa, MD discuss new drugs on the horizon.
Despite significant progress, there is a need to expand the therapeutic armamentarium for patients with myeloproliferative neoplasms (MPNs). Novel therapies in development include additional JAK inhibitors, MDM2 inhibitors (e.g., idasanutlin), histone deacetylase inhibitors, anti-fibrotics, and immunotherapy (e.g., long-acting interferon, monoclonal antibodies, checkpoint inhibitors and therapeutic vaccines). The potential applicability of CRISPR/Cas9 gene editing for MPNs is considered.